Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
-33.21M
Cash
77.97M
Avg Qtr Burn
-16.93M
Short % of Float
16.01%
Insider Ownership
8.70%
Institutional Own.
79.82%
Qtr Updated
12/31/24
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Bempikibart (ADX-914) Details Atopic dermatitis, Skin disease/disorder | Phase 2 Update | |
Bempikibart (ADX-914) Details Alopecia areata | Phase 2a Data readout | |
ADX-097 Details Renal disease, ANCA-Associated Vasculitis | Failed Discontinued | |
ADX-097 Details Renal disease, Lupus nephritis, IgA nephropathy, C3 Glomerulopathy | Failed Discontinued |